• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilars Articles for the Week of October 21

Article

The Center for Biosimilars® recaps the top stories for the week of October 21, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 21, 2019.

Number 5: The World Health Organization and the International Generic and Biosimilar Medicines Association have signed a memorandum of understanding on generics and biosimilars.

Number 4: Humana filed a lawsuit against more than 30 defendants whom it says engaged in a conspiracy to fix the prices of generic drugs.

Number 3: Researchers have now published detailed results from ABP 710’s phase 1 clinical study that evaluated the pharmacokinetic similarity of the biosimilar and reference infliximab.

Number 2: A recent survey of employers regarding their concerns about growing healthcare costs reveals that some are looking to biosimilars as one method of controlling specialty drug spending.

Number 1: During the United European Gastroenterology Week 2019 meeting, researchers presented results of a phase 1 pivotal study of a subcutaneously administered formulation of biosimilar infliximab, CT-P13, in patients with inflammatory bowel disease.

Finally, last week, our e-newsletter asked whether you think that you think that potential one-time therapies are likely to render high-cost eculizumab and its biosimilars less relevant.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
GBW 2023 webinar
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Christine Baeder
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Michael Kleinrock
Ian Henshaw
Ian Henshaw
John Gabrielson
Ryan Haumschild, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.